bryostatin-23

Bryostatin-23 is an investigational **small-molecule bryostatin analog** developed by **Aphios** as a next-generation PKC-modulating agent for neurodegenerative and other diseases. It is described as a potent **protein kinase C activator**, with reported enhancement of **alpha-secretase activity** and stronger activity than bryostatin-1 against multiple PKC isoforms, particularly **PKC delta** and **PKC epsilon**, in preclinical neuroblastoma models. The program has been positioned primarily for **Alzheimer's disease**, with additional preclinical interest in **glaucoma**, **herpesvirus infections**, and possibly oncology or inflammatory indications, but available evidence indicates that bryostatin-23 itself remains a **preclinical** asset rather than a clinically established medicine.

Other names

bryostatin 23bryostatin23bryostatin-23Bryoid-23Bryoid23Bryoid 23